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Conclusions: Activation of immune response in macrophages involved
in the development of ORG. Losing weight is beneficial to retard even
reverse the progression of ORG.
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Introduction: ADPKD is the most common renal genetic disease and the
fourth most common cause of end-stage renal disease (ESRD) world-
wide. Although PKD1 and PKD2 patients have different phenotypes,
there is also significant intra-familial variability in disease progression
suggesting that other genetic or environmental factors have major in-
fluences on disease progression. With the availability of new therapies,
there is now an urgent need to identify novel biomarkers which can
identify ADPKD patients at risk of rapid disease progression at an early
stage of disease.
Methods: Spot urine specimens were collected from consecutive
patients with ADPKD (n ¼ 130) attending a PKD clinic at the
Sheffield Kidney Institute and healthy controls (n ¼ 33). Urinary
exosomes were isolated by ultracentrifugation and confirmed by
electron microscopy and western blotting. The detection and
quantification of exosome-associated microRNAs in spot urine
samples from healthy volunteers, ADPKD patients with early (eGFR
> 60 ml/min) or late (eGFR < 60 ml/min) disease was by global RNA-
sequencing. Of the differentially expressed microRNAs commonly
identified by 3 algorithms, we chose several kidney-enriched
microRNAs from the same family (miR-30) or located at the same
gene cluster (miR-192/miR194) for further validation in a cohort of
60 participants using TaqMan qPCR assays.
Results: Electron microscopy confirmed the presence of multiple (<100
nm) vesicles in the pelleted fraction and western blotting detected the
presence of the exosome specific protein TSG-101 in the pellet,
demonstrating their origin from multivesicular bodies. In the discovery
cohort (n¼22), we identified a miRNA signature of down regulated
exosome small RNAs compared to controls, including three members of
the miR-30 family, miR-192-5p and miR-194-5p. All five kidney-
enriched microRNAs were also decreased in a validation cohort (n¼60).
Significantly, their expression was negatively correlated with eGFR,
positively correlated with mean kidney length, and were significantly
better predictors of the rate of disease progression in ADPKD (eGFR
slope < or >-3ml/min/year over 5 years) compared to mean kidney
length by ROC analysis.
Conclusions: By global microRNA profiling, we have identified an
exosome miRNA signature characteristic of ADPKD patients compared
to healthy controls. Exosome expression of members of the miR-30
family, miR-192-5p and miR-194-5p out performed mean kidney length
in identifying patients with rapid disease progression. Future studies
will seek to validate these findings in additional patient cohorts and to
compare their performance with that of other accepted or novel disease
biomarkers. Our ultimate goal is to improve risk prediction in patients
with early disease, to identify those who could benefit from earlier and
more intensive intervention.
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Introduction: Autosomal dominant polycystic kidney disease
(ADPKD) is caused by mutations in either PKD1 or PKD2, encoding
for the proteins polycystin-1 (PC1) or polycystin-2 (PC2), respec-
tively. The exact function of polycystins in cyst formation remains
unclear. Renal stress has been proposed to enhance cystogenesis,
while altered autophagy has recently been implicated in ADPKD
progression. We therefore aimed to investigate the cellular response
towards nutritional stress in mouse inner medullary collecting duct
cells (IMCDs), either wild-type (WT) or lacking PC1 or PC2 (PC1KO
or PC2KO), with a focus on cell survival (autophagy) and cell death
(apoptosis). Results were validated in human urine-derived prox-
imal tubular epithelial cells from early-stage ADPKD patients versus
healthy individuals.
Methods: Autophagy was measured by LC3 immunoblotting and by
counting GFP-LC3 punctae. Cell death was assessed by the levels of
cleaved Caspase 3, FITC-Annexin V/PI staining and Trypan Blue
exclusion assay.
Results: PC1KO and PC2KO IMCDs were more resistant against
nutrient stress, with reduced cell death compared to WT following
72 h of starvation. Basal and starvation-induced autophagy (3 h) was
enhanced in PC1KO, while the latter was suppressed in PC2KO
IMCDs. However, 48 h following starvation, higher autophagy
levels in both PC1KO and PC2KO IMCDs were observed compared to
WT IMCDs, suggesting that polycystins regulate the transition from
autophagy to cell death. Increased resistance towards starvation
associated with elevated autophagy was also observed in human
ADPKD cells. Inhibition of autophagy reduced nutrient stress
resistance in the polycystin-deficient cells, suggesting that the
increased survival is due to enhanced autophagy. Moreover, these
findings were dependent on a reciprocal regulation of polycystins,
in which PC1 suppresses PC2 and PC2 enhances PC1 levels during
nutrient starvation. Interestingly, following recovery, PC1 KO
showed higher proliferation and mTOR activity compared to WT
IMCDs.
Conclusions: Our data suggest that PC1 and PC2 determine the cell
death versus survival response during nutritional stress. As such,
polycystin-deficient cells display suppressed apoptosis and enhanced
autophagy resulting in more cell survival during nutrient starvation
than WT cells. Consequently, polycystin-deficient cells have an
increased proliferation rate following recovery from the stress. This
mechanism suggests how stress is able to amplify cystogenesis in
ADPKD.
SAT-444
GENOTYPE - PHENOTYPE CORRELATION
IN A PEDIATRIC ADPKD COHORT
VAN GIEL, D1,2, De Rechter, S1,3, Breysem, L4, Hindryckx, A5,
Janssens, P1, Decuypere, JP1, Bammens, B6,7, Corveleyn, A8,
Ferec, C9, Vennekens, R2, Harris, P10, Audrézet, MP9, Mekahli, D*1,3
1KU Leuven PKD Research Group- Department of Development and
Regeneration Leuven Belgium, 2KU Leuven Laboratory of Ion Channel
Research- Department of Cellular and Molecular Medicine Leuven Belgium,
3University Hospitals Leuven Department of Pediatric Nephrology Leuven
Belgium, 4University Hospitals Leuven Department of Radiology Leuven
Belgium, 5University Hospitals Leuven Department of Gynaecology and
Obstetrics Leuven Belgium, 6KU Leuven Department of Microbiology and
Immunology Leuven Belgium, 7University Hospitals Leuven Department of
Nephrology- Dialysis and Renal Transplantation Leuven Belgium, 8Univer-
sity Hospitals Leuven Centre for Human Genetics Leuven Belgium, 9Institut
National de la Santé et de la Recherche Médicale Laboratory of Molecular
Genetics and Histocompatibility- University Hospital of Brest Brest France,
10Mayo Clinic College of Medicine Division of Nephrology and Hyperten-
sion Rochester- Minnesota USA
ISN WCN 2020, ABU DHABI, UAE
Kidney International Reports (2020) 5, S1–S392 S185
